Ajinomoto Bio-Pharma Services is a fully integrated contract development and manufacturing organization with sites in Belgium, the United States, Japan, and India. The company provides comprehensive development, cGMP manufacturing, and aseptic fill finish services for small and large molecule APIs and intermediates. Ajinomoto Bio-Pharma Services offers a broad range of innovative platforms and capabilities for pre-clinical and pilot programs to commercial quantities, including: Corynex® protein expression technology, oligonucleotide synthesis, antibody drug conjugations (ADC), high potency APIs (HPAPI), biocatalysis, continuous flow manufacturing, and more. Founded in 1998, Ajinomoto Bio-Pharma Services operates within the industries of Analytics, Biopharma, Biotechnology, and Health Care. The company is dedicated to providing a high level of quality and service to meet its client’s needs. For more information, visit www.AjiBio-Pharma.com.
There is no investment information
No recent news or press coverage available for Ajinomoto Bio-Pharma Services.